Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden Anstalt des öffentlichen Rechts des Freistaates Sachsen
ZKN Logo
  • The Center
    • Multiple Sclerosis Center Dresden
      • Patient Information
      • Contact MSC
      • Physicians & Nurses
      • Study Team
      • Neuropsychology
    • Mobility Center
      • The Mobility Center
      • Walking Assessment
      • Jump Assessment
      • DIERS
      • EMIQ
      • Projects
    • Neuroimmunological Laboratory
      • The NIL
      • Neurofilament light chain
    • Autonomic & Neuroendocrinological Functional Laboratory
      • The ANF
      • ANF Assessment
    • MS Living Lab
    • Management & Science
      • Team Management & Science
      • Projects
      • eHealth & Analytics
        • MSDS 3D
        • MSDS Clinic & Practice
        • MS-HRS
        • MTRS
      • Multiple Sclerosis Management
  • Aktuelles
    • Neuigkeiten
    • Publikationen
    • Veranstaltungen
      • Adventssymposium
      • Multiple Sklerose 360°
      • Welt-MS-Tag 2021
    • Doktorarbeiten
    • Jobs
    • Kontakt
  • Podcasts & Newsletter
    • Newsletter
    • Patienten-Podcast
    • Ärzte-Podcast
    • Neurovision
  • Studien
    • Interventionelle Studien
    • B-SHUTTLE
    • Nicht-interventionelle Studien
    • MS PATHS
    • Konectom
    • Sprachanalyse
English (UK)
Deutsch
English (UK)

Treatment of multiple sclerosis with glatiramer acetate - New information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies

MS Treatments

Jahr

Publikationsjahr
2002

Autoren

Autorenliste der Publikation
Ziemssen T, Neuhaus O, Farina C, Hartung HP, Hohlfeld R.

Verlag

Publisher-Information
Nervenarzt 2002;73(4):321-331.

Link

Zur Publikation (externer Server)
https://link.springer.com/article/10.1007/s00115-001-1257-0

Tags

Forschungsthemen
Multiple SkleroseMS Behandlung
MSZTreatments2002

  • RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

    Other
    Jahr
    2024

  • Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease

    Multiple Sclerosis
    Jahr
    2024

  • Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

    Multiple Sclerosis
    Jahr
    2024

  • MS brain health quality standards: a survey on the reality in clinical practice in Germany

    Multiple Sclerosis
    Jahr
    2024

  • Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

    MS Treatments
    Jahr
    2024
  • Start
  • Aktuelles
  • Publikationen
  • MS Treatments
  • Treatment of multiple sclerosis with glatiramer acetate - New information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies
Impressum & Datenschutz

© 2024
Universitätsklinikum C.G. Carus Dresden an der Technischen Universität Dresden